LIFE / aTyr Pharma, Inc. (LIFE) CEO Dr. Sanjay S. Shukla on Q1 2022 Results - Earnings Call Transcript

Atyr Pharma (LIFE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with str more_horizontal

Atyr Pharma (LIFE) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of more_horizontal

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of fi more_horizontal

Atyr Pharma (LIFE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of more_horizontal

aTyr Pharma, Inc. (NASDAQ:LIFE ) Q4 2022 Earnings Conference Call March 9, 2023 5:00 PM ET Company Participants Ashlee Dunston - Director, Investor Re more_horizontal

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 45.83% and 592.40%, respectively, for the quarter ended December 2022. Do the numbers h more_horizontal

Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). more_horizontal

aTyr Pharma, Inc. (NASDAQ:LIFE ) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Ashlee Dunston - Director, IR & Co more_horizontal